American Academy of Allergy, Asthma & Immunology

Data featured at the AAAAI 2023 Annual Meeting revealed that children with current or prior SARS-CoV-2 infection had more autoantibodies than healthy children.

In a presentation at the AAAAI 2023 Annual Meeting, new data suggested that treating early symptoms may be a viable strategy for preventing acute attacks in patients with hereditary angioedema (HAE).

New data presented at the 2023 AAAAI Annual Meeting indicated that infants with anaphylaxis had different symptoms from those who were older, with greater involvement in other areas.

In another recent HCPLive interview at AAAAI, Altman described examples of systems biology approaches to allergic disease and the importance of cross-disciplinary collaboration.

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

Altman spoke in a recent interview about the main takeaways from his AAAAI presentation, during which he discussed systems biology research into allergic diseases.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

According to data from the AAAAI 2023 Annual Meeting, individuals with food allergies face numerous barriers when managing their condition while flying, with only 15% receiving epinephrine.

"We are looking at trying to satisfy a truly unmet medical need," Dr. David Dworaczyk says about the development of a new epinephrine nasal spray for anaphylaxis.

Dr. David Dworaczyk explains phase 3 data showing a single intranasal dose of epinephrine produced a higher and more prolonged plasma curve compared to an intramuscular 0.3 mg autoinjector.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

A study from the AAAAI 2023 Annual Meeting reveals racial and ethnic disparities in the management of severe asthma and highlights the need for interventions to improve care escalation for Black and Hispanic/Latino patients.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’

Those who are underweight or normal weight were more likely to have an IgE mediated food allergy.

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

Gestational age and NICU admission both were associated with the risk of developing EoE.

The reductions were seen as early as week 2 and was sustained throughout the 52 week study.

The algorithm also resulted in a large reduction in oral food challenges.

Additionally, the association between atopic dermatitis and sensitization to eggs was more common during the pandemic then in years prior.

By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.

Investigators examined data on abrocitinib from the JADE REGIMEN study.